All Blogs
Feb 06, 2026
Menin Inhibitors: A Revolutionary Treatment Paradigm for Acute Leukemia
Summary Menin inhibitors are an emerging class of targeted therapies that transform treatment for genetically defined acute leukemias, particularly KMT2A‑rearranged and NPM1‑mutated AML. REVUFORJ (revumenib, Syndax) is the first FDA‑approved selective menin inhibitor for relapsed/refractory acute leukemia wi...
Read More...
Feb 05, 2026
GE HealthCare Secures FDA 510(k) Clearance and CE Mark for Allia Moveo, Completing First Global Installation; China NMPA Approves Promega’s MSI Test as a Companion Diagnostic for KEYTRUDA; Oracle Life Sciences AI Data Platform Unifies Data and Agentic Intelligence to Accelerate Breakthroughs and Boost Commercial Outcomes; Quest Diagnostics Launches New Blood Test for Detecting Minimal Residual Myeloma; RevBio Secures FDA Clearance to Begin Pivotal Study of Cranial Bone Glue; Hyperfine Reports Breakthrough Clinical Findings on Swoop® System’s Increased Sensitivity in Stroke Detection
GE HealthCare Announced the U.S. FDA 510(k) Clearance and CE Mark for Allia Moveo and marks first Global Installation, Advancing Precision Care in the Interventional Suite On February 02, 2026, GE HealthCare announced that Allia™ Moveo received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark...
Read More...
Feb 04, 2026
Top 8 Applications of Nanomedicine in Healthcare
As we navigate, the medical landscape is undergoing a silent but profound transformation. We have officially moved beyond the era of "one-size-fits-all" medicine and entered the age of Precision Health, driven largely by the maturity of nanomedicine. While traditional medicine has long relied on macroscopic interve...
Read More...
Feb 03, 2026
Novo Nordisk A/S Announces that CagriSema Delivered Superior Outcomes in REIMAGINE 2; Sanofi’s Venglustat Clears all Primary Hurdles in Phase 3 Gaucher Disease Trial; Kyowa Kirin Reacquires Full Development and Commercialization Rights for Rocatinlimab; IMFINZI Receives CHMP Recommendation for Perioperative Treatment in Patients with Resectable Gastric and Gastroesophageal Cancers; Tenpoint Wins FDA Approval for First-Ever Combination Presbyopia Eye Drop
Novo Nordisk A/S Reports that CagriSema Achieved a 1.91-percentage-point HbA1c Reduction and 14.2% Weight Loss in Adults with Type 2 Diabetes in the REIMAGINE 2 Study Novo Nordisk announced top-line findings from REIMAGINE 2, a phase 3 study within the global REIMAGINE programme. The results show that CagriSema ...
Read More...
Feb 02, 2026
Cystinosis Treatment: Transforming a Life-Limiting Disorder into a Manageable Chronic Condition
Summary Approximately 1,600 prevalent cases were diagnosed across the 7MM in 2025, underscoring the condition's rarity and the concentration of patients at specialized metabolic and nephrology centers. Treatment is limited to long-standing cysteamine products, PROCYSBI, CYSTAGON/NICYSTAGON (cysteamine bitart...
Read More...
Jan 30, 2026
DAWNZERA’s EU Approval Strengthens the Hereditary Angioedema Treatment Landscape
Summary The European Commission granted marketing authorization for DAWNZERA (donidalorsen) on January 21, 2026. Developed by Ionis Pharmaceuticals and Otsuka Pharmaceutical, it is the first and only RNA-targeted therapy approved in the EU for the prevention of hereditary angioedema (HAE). Approval ...
Read More...
Jan 29, 2026
Seno Medical Secures EU MDR CE Mark for Next-Generation Imagio® Imaging System; Spine Innovation Announces FDA 510(k) Clearance of LOGIC™ Titanium Expandable Interbody System; Laborie Adds JADA® System to Obstetrics Portfolio for Rapid PPH Control; Olympus Introduces SecureFlex™ Single-Use Fine Needle Biopsy Device in the U.S.; Kardium Publishes PULSAR Pivotal Trial Findings in JACC; Myra Vision Begins U.S. ADAPT Glaucoma Study, Treating First Participant
Seno Medical’s Next-Generation Imagio® Imaging System Obtained European Union (EU) Medical Device Regulation (MDR) CE Mark Certification On January 26, 2026, Seno Medical received CE Mark certification for its next-generation Imagio® Imaging System, Model 9100, confirming that the device met the stringent ...
Read More...
Jan 28, 2026
Advances in Varicose Vein Treatment Devices: Technologies Shaping Modern Venous Care
Varicose veins, enlarged, tortuous veins most commonly occurring in the lower extremities, impact millions worldwide, causing discomfort, cosmetic concerns, and, in severe cases, complications such as venous insufficiency or ulcers. While traditional varicose vein treatments such as compression stockings and surgic...
Read More...
Jan 27, 2026
Sanofi Strengthens Amlitelimab’s Position in Atopic Dermatitis; Corcept Announces Statistically Significant Overall Survival Benefit in Phase 3 ROSELLA Study; CORXEL Raises $287M Series D1 for Cardiometabolic Pipeline Expansion; IntraBio’s Levacetylleucine Demonstrates Positive Results in Pivotal Ataxia-Telangiectasia Trial; Otsuka Secures FDA Acceptance and Priority Review for Centanafadine in ADHD
Sanofi’s Amlitelimab Demonstrates Promise in Atopic Dermatitis Following the positive findings from the COAST 1 trial (NCT06130566) reported in September 2025, two additional global Phase 3 studies, SHORE (NCT06224348) and COAST 2 (NCT06181435), have further strengthened the clinical evidence supporting amliteli...
Read More...
Jan 26, 2026
ASPAVELI Fuels Sobi’s Growth Strategy in Europe for C3G and IC-MPGN
Summary Sobi has received European Commission approval for ASPAVELI (pegcetacoplan) to treat C3G and primary IC-MPGN, two rare, progressive kidney diseases. The approval follows a positive CHMP opinion (December 2025) and marks the first approved treatment for primary IC-MPGN and the first for both C3G...
Read More...